Dataset Information

DLAB: deep learning methods for structure-based virtual screening of antibodies.

ABSTRACT:

Motivation

Antibodies are one of the most important classes of pharmaceuticals, with over 80 approved molecules currently in use against a wide variety of diseases. The drug discovery process for antibody therapeutic candidates however is time- and cost-intensive and heavily reliant on in vivo and in vitro high throughput screens. Here, we introduce a framework for structure-based deep learning for antibodies (DLAB) which can virtually screen putative binding antibodies against antigen targets of interest. DLAB is built to be able to predict antibody-antigen binding for antigens with no known antibody binders.

Results

We demonstrate that DLAB can be used both to improve antibody-antigen docking and structure-based virtual screening of antibody drug candidates. DLAB enables improved pose ranking for antibody docking experiments as well as selection of antibody-antigen pairings for which accurate poses are generated and correctly ranked. We also show that DLAB can identify binding antibodies against specific antigens in a case study. Our results demonstrate the promise of deep learning methods for structure-based virtual screening of antibodies.

Availability and implementation

The DLAB source code and pre-trained models are available at https://github.com/oxpig/dlab-public.

Supplementary information

Supplementary data are available at Bioinformatics online.

SUBMITTER: Schneider C

PROVIDER: S-EPMC8723137 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

DLAB: deep learning methods for structure-based virtual screening of antibodies.

Schneider Constantin C Buchanan Andrew A Taddese Bruck B Deane Charlotte M CM

Bioinformatics (Oxford, England) 20220101 2

<h4>Motivation</h4>Antibodies are one of the most important classes of pharmaceuticals, with over 80 approved molecules currently in use against a wide variety of diseases. The drug discovery process for antibody therapeutic candidates however is time- and cost-intensive and heavily reliant on in vivo and in vitro high throughput screens. Here, we introduce a framework for structure-based deep learning for antibodies (DLAB) which can virtually screen putative binding antibodies against antigen t ...[more]

PMID: 34546288

Similar Datasets

Project description:Traditional drug production is a long and complex process that leads to new drug production. The virtual screening technique is a computational method that allows chemical compounds to be screened at an acceptable time and cost. Several databases contain information on various aspects of biologically active substances. Simple statistical tools are difficult to use because of the enormous amount of information and complex data samples of molecules that are structurally heterogeneous recorded in these databases. Many techniques for capturing the biological similarity between a test compound and a known target ligand in LBVS have been established. However, despite the good performances of the above methods compared to their prior, especially when dealing with molecules that have homogeneous active structural elements, they are not satisfied when dealing with molecules that are structurally heterogeneous. Deep learning models have recently achieved considerable success in a variety of disciplines due to their powerful generalization and feature extraction capabilities. Also, the Siamese network has been used in similarity models for more complicated data samples, especially with heterogeneous data samples. The main aim of this study is to enhance the performance of similarity searching, especially with molecules that are structurally heterogeneous. The Siamese architecture will be enhanced using two similarity distance layers with one fusion layer to further improve the similarity measurements between molecules and then adding many layers after the fusion layer for some models to improve the retrieval recall. In this architecture, several methods of deep learning have been used, which are long short-term memory (LSTM), gated recurrent unit (GRU), convolutional neural network-one dimension (CNN1D), and convolutional neural network-two dimensions (CNN2D). A series of experiments have been carried out on real-world data sets, and the results have shown that the proposed methods outperformed the existing methods.

Project description:BackgroundThe study objective was to determine whether unlabeled datasets can be used to further train and improve the accuracy of a deep learning system (DLS) for the detection of tuberculosis (TB) on chest radiographs (CXRs) using a two-stage semi-supervised approach.MethodsA total of 111,622 CXRs from the National Institute of Health ChestX-ray14 database were collected. A cardiothoracic radiologist reviewed a subset of 11,000 CXRs and dichotomously labeled each for the presence or absence of potential TB findings; these interpretations were used to train a deep convolutional neural network (DCNN) to identify CXRs with possible TB (Phase I). The best performing algorithm was then used to label the remaining database consisting of 100,622 radiographs; subsequently, these newly-labeled images were used to train a second DCNN (phase II). The best-performing algorithm from phase II (TBNet) was then tested against CXRs obtained from 3 separate sites (2 from the USA, 1 from China) with clinically confirmed cases of TB. Receiver operating characteristic (ROC) curves were generated with area under the curve (AUC) calculated.ResultsThe phase I algorithm trained using 11,000 expert-labelled radiographs achieved an AUC of 0.88. The phase II algorithm trained on images labeled by the phase I algorithm achieved an AUC of 0.91 testing against a TB dataset obtained from Shenzhen, China and Montgomery County, USA. The algorithm generalized well to radiographs obtained from a tertiary care hospital, achieving an AUC of 0.87; TBNet's sensitivity, specificity, positive predictive value, and negative predictive value were 85%, 76%, 0.64, and 0.9, respectively. When TBNet was used to arbitrate discrepancies between 2 radiologists, the overall sensitivity reached 94% and negative predictive value reached 0.96, demonstrating a synergistic effect between the algorithm's output and radiologists' interpretations.ConclusionsUsing semi-supervised learning, we trained a deep learning algorithm that detected TB at a high accuracy and demonstrated value as a CAD tool by identifying relevant CXR findings, especially in cases that were misinterpreted by radiologists. When dataset labels are noisy or absent, the described methods can significantly reduce the required amount of curated data to build clinically-relevant deep learning models, which will play an important role in the era of precision medicine.

Dataset Information

DLAB: deep learning methods for structure-based virtual screening of antibodies.

Motivation

Results

Availability and implementation

Supplementary information

Publications

DLAB: deep learning methods for structure-based virtual screening of antibodies.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets